Navigation Links
Rib-X Granted Key Antibiotic Patent in China
Date:4/15/2009

NEW HAVEN, Conn., April 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic-resistant infections, today announced the issuance of a key antibiotic patent in China. The State Intellectual Property Office of the People's Republic of China has issued Chinese Patent Number ZL 2004 8 0021883.9 to Rib-X. This patent provides composition of matter protection for Rib-X's novel oxazolidinone antibiotic, radezolid. Rib-X has established a broad patent portfolio related to radezolid, including the issuance of composition of matter for radezolid in the US. The Company anticipates issuance of additional patents in all major and emerging markets.

"This Chinese patent strengthens Rib-X's existing intellectual property portfolio and underscores our ability to successfully design and develop antibiotics that overcome resistant bacteria," said Susan Froshauer, Ph.D., President and CEO of Rib-X Pharmaceuticals. "China is the world's largest emerging pharmaceutical market, and the issuance of this patent enhances Rib-X's commercial opportunities in this important region of the world."

About Radezolid

Radezolid is a novel oxazolidinone that was discovered using Rib-X's proprietary discovery process and was designed to expand the bacterial spectrum and improve the utility of this class of antibiotics relative to the only other oxazolidinone marketed in the world, Zyvox(R) (linezolid). Rib-X is developing both oral and IV formulations for use in serious hospital gram positive infections, including those caused by MRSA and linezolid- and vancomycin-resistant enterococci. Radezolid is the subject of a second ongoing Phase 2 clinical trial for community acquired pneumonia (CAP). This compound has been shown to be microbiologically more active than linezolid against Gram-positive organisms, including potent activity against linezolid resistant bacteria, in prior studies.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many known, commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can be used for the treatment of either community- or hospital-acquired infections. In addition to delafloxacin, Rib-X is currently in Phase 2 trials with radezolid (RX-1741), an oxazolidinone that was discovered at Rib-X, as an oral/IV agent for treatment of serious Gram-positive infections. The Rx-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria and the Rx-02 discovery program is focused on developing an IV/oral macrolide active against methicillin-resistant S. aureus, multidrug-resistant Streptococcus pneumoniae and S. pyogenes. Both delafloxacin and radezolid are currently in Phase 2 clinical trials.

For more information on Rib-X, please visit the Company website at www.rib-x.com.


'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
2. Rib-X CEO Susan Froshauer, PhD, Honored by The Connecticut Womens Hall of Fame
3. MonoSol Rx Granted U.S. Article of Manufacture Patent
4. Microfluidic Systems (MFSI) is Granted a Microfluidic Cartridge Patent for DNA Separation
5. Skinvisible Patent Granted for Japan
6. Lilly Granted Temporary Restraining Order to Halt Launch of Generic Raloxifene
7. The 2009 Damon Runyon-Rachleff Innovation Award Granted for Pioneering Ideas for Early Detection of Ovarian and Lung Cancers, Bone Marrow Transplant Safety, and Discovery of New Genetic Markers for Cancer
8. Lupin is Granted USFDA Approval for Levetiracetam Tablets
9. Accreditation to the International Standards Organization for Quality Management Granted to First U.S. Lab
10. PURE Bioscience Granted US Patent on SDC for Food Treatment
11. Access Granted to Present at the Collaborative Communications Summit: Health Technology Investment Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
(Date:6/24/2016)... ... ... Comfort Keepers® of San Diego, CA is excited to announce they are ... drive cancer patients to and from their cancer treatments. Comfort Keepers provides quality ... and ongoing independence. Getting to and from medical treatments is one of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon and the ... in the world, and the most handsome men, look naturally attractive. Plastic surgery ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Venture Construction ... Classic Tournament held on June 20th at the Woodmont Country Club at 1201 ... Wings, an organization dedicated to helping service members that have been wounded in battle ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
Breaking Medicine Technology: